| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | BRD-K13999467 | CTRPv2 | pan-cancer | AAC | -0.003 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |